Rivas provides excellent care
Key details regarding the July 2026 review: July 23, 2026 Review: BPC-157 (wound/injury), KPV (inflammation), TB-500 (wound healing), and MOTs-C (obesity/osteoporosis)
GLP3, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Nano-Particle Absorption: Utilizing advanced microfluidizer technology, the active nutrients are shrunk into tiny particles that bypass the surface to nourish the deeper layers of the skin
Harris, I., Treloar, A., Inoue, S., Sasaki, M., Gorrini, C., Lee, K
These innovative formulations break down glutathione, vitamin D3 with K2, or methyl B12 into nano-particles for superior absorption and faster results